| 1. |
- Simard, Julia F., et al.
(författare)
-
Ten years with biologics : to whom do data on effectiveness and safety apply?
- 2011
-
Ingår i: Rheumatology. - : Oxford University Press (OUP). - 1462-0324 .- 1462-0332. ; 50:1, s. 204-213
-
Tidskriftsartikel (refereegranskat)abstract
- Methods. We identified all adult patients with RA (n = 9612), PsA (n = 1417) and other SpA (n = 1652) initiating a first biologic therapy between 1 January 1999 and 31 December 2008, registered in the Swedish Biologics Register (ARTIS), including information on demographics, disease characteristics and 1-year risk of first-line treatment discontinuation. Results. Over calendar time, measures of disease activity at start declined substantially for all indications, and diminished between first-, second- and third-line therapy starts. One-year risks of first-line therapy discontinuation increased. Switchers to anti-TNF and non-TNF biologics had different comorbidities. Despite < 50% drug retention at 5 years, most patients remained exposed to some biologic. Conclusions. The trends in baseline characteristics and drug retention underscores that any effects of biologics, including comparison between different biologics, must be interpreted in light of the characteristics of the population treated. The observed differences further call for continued vigilance to properly evaluate the safety profiles of biologic treatments as they are currently used. Exposure to multiple biologics presents a challenge for attribution of long-term effects.
|
|
| 2. |
- Cöster, Maria, et al.
(författare)
-
Comparison of the Self-Reported Foot and Ankle Score (SEFAS) and the American Orthopedic Foot and Ankle Society Score (AOFAS)
- 2014
-
Ingår i: Foot & ankle international. - Thousand Oaks, CA : SAGE Publications (UK and US): 12 month Embargo. - 1071-1007 .- 1944-7876. ; 35:10, s. 1031-1036
-
Tidskriftsartikel (refereegranskat)abstract
- Background: The Self-reported Foot and Ankle Score (SEFAS) is a patient-reported outcome measure, while the American Orthopedic Foot and Ankle Society Score (AOFAS) is a clinician-based score, both used for evaluation of foot and ankle disorders. The purpose of this study was to compare the psychometric properties of these 2 scoring systems. Methods: A total of 95 patients with great toe disorders and 111 patients with ankle or hindfoot disorders completed the 2 scores before and after surgery. We evaluated time to complete the scores in seconds, correlations between scores with Spearmans correlation coefficient (r(s)), floor and ceiling effects by proportion of individuals who reached the minimum or maximum values, test-retest reliability and interobserver reliability by intraclass correlation coefficient (ICC), internal consistency by Cronbachs coefficient alpha (CA), and responsiveness by effect size (ES). Data are provided as correlation coefficients, means, and standard deviations. Results: SEFAS was completed 3 times faster than AOFAS. The scores correlated with an r(s) of .49 for great toe disorders and .67 for ankle/hindfoot disorders (both P less than .001). None of the scores had any floor or ceiling effect. SEFAS test-retest ICC values measured 1 week apart were .89 for great toe and .92 for ankle/hindfoot disorders, while the corresponding ICC values for AOFAS were .57 and .75. AOFAS interobserver reliability ICC values were .70 for great toe and .81 for ankle/hindfoot disorders. SEFAS CA values were .85 for great toe and .86 for ankle/hindfoot disorders, while the corresponding CA values for AOFAS were .15 and .42. SEFAS ES values were 1.15 for great toe and 1.39 for ankle/hindfoot disorders, while the corresponding ES values for AOFAS were 1.05 and 1.73. Conclusion: As SEFAS showed similar or better outcome in our tests and was completed 3 times faster than AOFAS, we recommend SEFAS for evaluation of patients with foot and ankle disorders.
|
|
| 3. |
- Djukanovic, Ingrid, et al.
(författare)
-
Health-related quality of life in patients before and after planned orthopedic surgery : a prospective follow-up study
- 2011
-
Ingår i: International Journal of Orthopaedic and Trauma Nursing. - : Elsevier. - 1878-1241 .- 1878-1292. ; 15:4, s. 185-195
-
Tidskriftsartikel (refereegranskat)abstract
- BackgroundThere are increasing demands on health care for both results and quality. Treatment outcome from the patient’s perspective is essential but not often demanded. The aim of the study was to assess Health Related Quality of Life (HRQoL) prior to and one year after an elective orthopedic intervention.MethodsHRQoL was evaluated by the 5-dimensional scale of the EuroQoL (EQ5D) with two additional scales, EQVAS and PainVAS in 676 consecutive patients undergoing 120 different elective orthopedic interventions. Descriptive statistics were used.ResultsResults showed patients treated for arthrosis with total hip and knee replacement had the greatest improvement in HRQoL. Patients that underwent spinal, upper arm and arthroscopic knee surgery showed considerable improvement. All patients experienced pain relief one year after surgery. Changes in the three effect variables EQ5D, EQVAS and PainVAS correlated significantly with each other.ConclusionsThe study provides an overview of patient assessment of HRQoL before and after some of the most common elective orthopedic interventions. Knowledge obtained from patient groups should help improve and individualize care both from a nursing and surgical perspective.
|
|
| 4. |
|
|
| 5. |
- Kastbom, Alf, et al.
(författare)
-
Influence of FCGR3A genotype on the therapeutic response to rituximab in rheumatoid arthritis : an observational cohort study
- 2012
-
Ingår i: BMJ Open. - : BMJ. - 2044-6055. ; 2:5
-
Tidskriftsartikel (refereegranskat)abstract
- Objectives To determine whether a polymorphism in the Fcγ receptor type IIIA (FCGR3A-F158V), influencing immunoglobulin G binding affinity, relates to the therapeutic efficacy of rituximab in rheumatoid arthritis (RA) patients.Design Observational cohort study.Setting Three university hospital rheumatology units in Sweden.Participants Patients with established RA (n=177; 145 females and 32 males) who started rituximab (Mabthera) as part of routine care.Primary outcome measures Response to rituximab therapy in relation to FCGR3A genotype, including stratification for sex.Results The frequency of responders differed significantly across FCGR3A genotypes (p=0.017 in a 3×2 contingency table). Heterozygous patients showed the highest response rate at 83%, as compared with patients carrying 158FF (68%) or 158VV (56%) (p=0.028 and 0.016, respectively). Among 158VV patients, response rates differed between male and female patients (p=0.036), but not among 158FF or 158VF patients (p=0.72 and 0.46, respectively).Conclusions Therapeutic efficacy of rituximab in RA patients is influenced by FCGR3A genotype, with the highest response rates found among heterozygous patients. This may suggest that different rituximab mechanisms of action in RA are optimally balanced in FCGR3A-158VF patients. Similar to the previously described associations with RA susceptibility and disease course, the impact of 158VV on rituximab response may be influenced by sex.
|
|
| 6. |
|
|
| 7. |
|
|
